Literature DB >> 25806210

Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial.

Alejandro Navarro Mendivil1, Pablo Martinez Rodriguez1, Enriqueta Felip1.   

Abstract

Entities:  

Year:  2013        PMID： 25806210      PMCID： PMC4367637          DOI： 10.3978/j.issn.2218-6751.2012.09.12

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  30 in total

1.  Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.

Authors:  Fabio A B Schutz; Youjin Je; Christopher J Richards; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2012-02-06       Impact factor: 44.544

2.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.

Authors:  John D Hainsworth; Jeffrey A Sosman; David R Spigel; Donna L Edwards; Cara Baughman; Anthony Greco
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

Review 3.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

4.  Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

Authors:  Hans-Peter Gerber; Napoleone Ferrara
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

5.  International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

Authors:  Giorgio V Scagliotti; Ihor Vynnychenko; Keunchil Park; Yukito Ichinose; Kaoru Kubota; Fiona Blackhall; Robert Pirker; Rinat Galiulin; Tudor-Eliade Ciuleanu; Oleksandr Sydorenko; Mircea Dediu; Zsolt Papai-Szekely; Natividad Martinez Banaclocha; Sheryl McCoy; Bin Yao; Yong-Jiang Hei; Francesco Galimi; David R Spigel
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

Review 6.  Pathways mediating VEGF-independent tumor angiogenesis.

Authors:  Napoleone Ferrara
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-11       Impact factor: 7.638

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 8.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

Authors:  Napoleone Ferrara
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

9.  Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Bonne Biesma; David Heigener; Joachim von Pawel; Timothy Eisen; Jaafar Bennouna; Li Zhang; Meilin Liao; Yan Sun; Steven Gans; Kostas Syrigos; Etienne Le Marie; Maya Gottfried; Johan Vansteenkiste; Vincente Alberola; Uwe Phillip Strauss; Elaine Montegriffo; Teng Jin Ong; Armando Santoro
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

Authors:  John V Heymach; Luis Paz-Ares; Filippo De Braud; Martin Sebastian; David J Stewart; Wilfried E E Eberhardt; Anantbhushan A Ranade; Graham Cohen; Jose Manuel Trigo; Alan B Sandler; Philip D Bonomi; Roy S Herbst; Annetta D Krebs; James Vasselli; Bruce E Johnson
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.